Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma
Background Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine...
Uloženo v:
| Vydáno v: | Journal of translational medicine Ročník 22; číslo 1; s. 455 - 10 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
13.05.2024
BioMed Central Ltd BMC |
| Témata: | |
| ISSN: | 1479-5876, 1479-5876 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC.
Methods
Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model.
Results
A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well.
Conclusions
The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. |
|---|---|
| AbstractList | Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC.BACKGROUNDPatients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC.Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model.METHODSData on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model.A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well.RESULTSA total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well.The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients.CONCLUSIONSThe XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model. A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well. The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. Abstract Background Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC. Methods Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model. Results A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well. Conclusions The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. Background Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC. Methods Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model. Results A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well. Conclusions The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. Background Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC. Methods Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model. Results A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well. Conclusions The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. Keywords: Hepatocellular carcinoma, Predictive analytics, Survival, Machine learning, XGBoost algorithm Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time is one of the greatest concerns for patients with AFP-positive HCC. This study aimed to demonstrate the utilization of six machine learning (ML)-based prognostic models to predict overall survival of patients with AFP-positive HCC. Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient boosting [XGBoost], logistic regression [LR], support vector machine [SVM], random forest [RF], K-nearest neighbor [KNN], and decision tree [ID3]) were used to develop the prognostic models of patients with AFP-positive HCC at one year, three years, and five years. Area under the receiver operating characteristic curve (AUC), confusion matrix, calibration curves, and decision curve analysis (DCA) were used to evaluate the model. A total of 2,038 patients with AFP-positive HCC were included for analysis. The 1-, 3-, and 5-year overall survival rates were 60.7%, 28.9%, and 14.3%, respectively. Seventeen features regarding demographics and clinicopathology were included in six ML algorithms to generate a prognostic model. The XGBoost model showed the best performance in predicting survival at 1-year (train set: AUC = 0.771; test set: AUC = 0.782), 3-year (train set: AUC = 0.763; test set: AUC = 0.749) and 5-year (train set: AUC = 0.807; test set: AUC = 0.740). Furthermore, for 1-, 3-, and 5-year survival prediction, the accuracy in the training and test sets was 0.709 and 0.726, 0.721 and 0.726, and 0.778 and 0.784 for the XGBoost model, respectively. Calibration curves and DCA exhibited good predictive performance as well. The XGBoost model exhibited good predictive performance, which may provide physicians with an effective tool for early medical intervention and improve the survival of patients. |
| ArticleNumber | 455 |
| Audience | Academic |
| Author | Chen, Yongjian Dong, Bingtian Duan, Yayang Zhang, Hua Zhang, Chaoxue Yao, Senbang |
| Author_xml | – sequence: 1 givenname: Bingtian surname: Dong fullname: Dong, Bingtian organization: Department of Ultrasound, the First Affiliated Hospital of Anhui Medical University – sequence: 2 givenname: Hua surname: Zhang fullname: Zhang, Hua organization: Department of Ultrasound, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University – sequence: 3 givenname: Yayang surname: Duan fullname: Duan, Yayang organization: Department of Ultrasound, the First Affiliated Hospital of Anhui Medical University – sequence: 4 givenname: Senbang surname: Yao fullname: Yao, Senbang organization: Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Department of Oncology, Anhui Medical University – sequence: 5 givenname: Yongjian surname: Chen fullname: Chen, Yongjian email: 962106486@qq.com organization: Department of Ultrasound, The Second Affiliated Hospital of Fujian Medical University – sequence: 6 givenname: Chaoxue orcidid: 0000-0002-3037-8819 surname: Zhang fullname: Zhang, Chaoxue email: zcxay@163.com organization: Department of Ultrasound, the First Affiliated Hospital of Anhui Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38741163$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv3CAUha0qVfNo_0AXlaVuunEKxsawqqL0FSlSN-0aYbh4GNngAjNR_n3xOI0yVRWxAF2-c7hcnfPixHkHRfEWo0uMGf0Ycc1pV6G6qVBbI1LdvSjOcNPxqmUdPXlyPi3OY9yiTLYNf1WcEtY1GFNyVtx_hj2Mfp7ApdKbUpaTVBvroBxBBmfdUPUygi4nr2Esky_nANqqlHc_OB9tPMjGeSMrA8nncgLrqjlfJbuHcgOzTF7BOO5GGUolg7LOT_J18dLIMcKbh_2i-PX1y8_r79Xtj28311e3lWoZSlWvKaqpamrJJNe8IUwSRDvVAZhaIWM00T1ukVYaZajHpuGG4qanuOegKbkoblZf7eVWzMFOMtwLL604FHwYhAzJqhEEQbVmNWYcGdRwprkxHVU9lQiYMpxnr0-r17zrJ9AqDy3I8cj0-MbZjRj8XmCMeJ09s8OHB4fgf-8gJjHZuAxHOvC7mFtoG0Y4wQv6fkUHmXuzzvhsqRZcXHWcdBgTTDJ1-R8qLw2TVTkwxub6keDd0z88Nv83ExmoV0AFH2MA84hgJJbgiTV4IsdJHIIn7rKI_SNSNslk_TIHOz4vJas05nfcAEFs_S64nInnVH8AYsfv0Q |
| CitedBy_id | crossref_primary_10_3748_wjg_v31_i36_110742 crossref_primary_10_1016_j_fbio_2024_105368 crossref_primary_10_1007_s13304_025_02066_8 crossref_primary_10_2147_IJGM_S488418 crossref_primary_10_1038_s41598_025_09691_8 crossref_primary_10_3389_fmed_2025_1580345 crossref_primary_10_3389_fonc_2025_1585125 crossref_primary_10_1016_j_canlet_2025_217461 crossref_primary_10_1016_j_eujim_2025_102535 crossref_primary_10_1016_j_jceh_2025_103184 crossref_primary_10_1007_s12672_024_01541_9 crossref_primary_10_1186_s12957_025_03860_9 crossref_primary_10_1002_cam4_71008 |
| Cites_doi | 10.1186/s12967-023-04277-2 10.1007/s00330-023-09398-2 10.1007/s00432-023-04901-0 10.1038/s41598-020-78545-2 10.1093/ajcp/aqad143 10.1093/neuros/nyz403 10.1007/s11831-021-09648-w 10.1097/PAS.0000000000000749 10.1145/2939672.2939785 10.1002/cam4.3613 10.3322/caac.21660 10.1038/s41598-023-45438-z 10.1016/j.it.2022.04.001 10.1097/SLA.0b013e3181904988 10.1056/NEJMra1713263 10.1038/s41421-023-00563-x 10.1186/s13073-021-00968-x 10.1002/ags3.12057 10.1016/j.jhep.2004.11.042 10.1038/s41598-019-53863-2 10.1038/s41598-017-12834-1 10.1002/hep.1840120625 10.1038/s41598-021-85223-4 10.2147/CMAR.S177430 10.1146/annurev.bioeng.8.061505.095802 10.21037/jgo-22-1238 10.1515/cclm-2023-1037 10.2147/CMAR.S191287 10.3389/fonc.2020.00496 10.1007/s00134-003-1761-8 10.2196/42895 10.1038/s41598-023-42964-8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12967-024-05203-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_302d821890f0498d9ff76cb6a0e8cf99 PMC11092049 A793711313 38741163 10_1186_s12967_024_05203_w |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c580t-bd6026c42a8a9d9438a3067c7eef2c0ffd3db150dcd042ab1f49f614b61b9ed63 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001221748900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1479-5876 |
| IngestDate | Tue Oct 14 18:42:32 EDT 2025 Tue Nov 04 02:05:51 EST 2025 Thu Oct 02 09:33:15 EDT 2025 Sat Nov 29 14:04:18 EST 2025 Sat Nov 29 10:40:57 EST 2025 Mon Jul 21 06:06:14 EDT 2025 Sat Nov 29 04:16:16 EST 2025 Tue Nov 18 21:17:22 EST 2025 Sat Sep 06 07:28:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Hepatocellular carcinoma XGBoost algorithm Predictive analytics Survival Machine learning |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c580t-bd6026c42a8a9d9438a3067c7eef2c0ffd3db150dcd042ab1f49f614b61b9ed63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3037-8819 |
| OpenAccessLink | https://doaj.org/article/302d821890f0498d9ff76cb6a0e8cf99 |
| PMID | 38741163 |
| PQID | 3054839319 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_302d821890f0498d9ff76cb6a0e8cf99 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11092049 proquest_miscellaneous_3054839319 gale_infotracmisc_A793711313 gale_infotracacademiconefile_A793711313 pubmed_primary_38741163 crossref_primary_10_1186_s12967_024_05203_w crossref_citationtrail_10_1186_s12967_024_05203_w springer_journals_10_1186_s12967_024_05203_w |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-13 |
| PublicationDateYYYYMMDD | 2024-05-13 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAbbrev | J Transl Med |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | FM Suk (5203_CR2) 2019; 9 F Wu (5203_CR32) 2023; 33 K Taketa (5203_CR5) 1990; 12 JT Senders (5203_CR12) 2020; 86 MA Duggan (5203_CR18) 2016; 40 K Liu (5203_CR24) 2020; 10 J Jiang (5203_CR19) 2021; 11 R Yang (5203_CR23) 2023; 149 Z Xiao (5203_CR26) 2019; 11 PV Munson (5203_CR8) 2022; 43 T Zhao (5203_CR6) 2020; 10 DS Bai (5203_CR7) 2017; 7 C Cammà (5203_CR29) 2005; 42 KA Tran (5203_CR9) 2021; 13 F Kinoshita (5203_CR17) 2023; 13 H He (5203_CR4) 2023; 9 5203_CR13 YI Yamashita (5203_CR28) 2018; 2 Z Chen (5203_CR30) 2018; 10 P Sajda (5203_CR11) 2006; 8 Y Kumar (5203_CR21) 2022; 29 LY Yang (5203_CR27) 2009; 249 H Sung (5203_CR1) 2021; 71 HC Çubukçu (5203_CR20) 2023; 62 C Li (5203_CR15) 2023; 21 X Zhong (5203_CR16) 2023; 13 Q Xu (5203_CR14) 2022; 13 B Yan (5203_CR25) 2021; 10 A Villanueva (5203_CR3) 2019; 380 TT Nguyen (5203_CR10) 2023; 7 JE Fischer (5203_CR22) 2003; 29 5203_CR31 |
| References_xml | – volume: 21 start-page: 404 issue: 1 year: 2023 ident: 5203_CR15 publication-title: J Transl Med doi: 10.1186/s12967-023-04277-2 – volume: 33 start-page: 3604 issue: 5 year: 2023 ident: 5203_CR32 publication-title: Eur Radiol doi: 10.1007/s00330-023-09398-2 – volume: 149 start-page: 10099 issue: 12 year: 2023 ident: 5203_CR23 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-023-04901-0 – volume: 10 start-page: 21376 issue: 1 year: 2020 ident: 5203_CR24 publication-title: Sci Rep doi: 10.1038/s41598-020-78545-2 – ident: 5203_CR31 doi: 10.1093/ajcp/aqad143 – volume: 86 start-page: E184 issue: 2 year: 2020 ident: 5203_CR12 publication-title: Neurosurgery doi: 10.1093/neuros/nyz403 – volume: 29 start-page: 2043 issue: 4 year: 2022 ident: 5203_CR21 publication-title: Arch Comput Methods Eng doi: 10.1007/s11831-021-09648-w – volume: 40 start-page: e94 issue: 12 year: 2016 ident: 5203_CR18 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000749 – ident: 5203_CR13 doi: 10.1145/2939672.2939785 – volume: 10 start-page: 496 issue: 2 year: 2021 ident: 5203_CR25 publication-title: Cancer Med doi: 10.1002/cam4.3613 – volume: 71 start-page: 209 issue: 3 year: 2021 ident: 5203_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 13 start-page: 18301 issue: 1 year: 2023 ident: 5203_CR16 publication-title: Sci Rep doi: 10.1038/s41598-023-45438-z – volume: 43 start-page: 438 issue: 6 year: 2022 ident: 5203_CR8 publication-title: Trends Immunol doi: 10.1016/j.it.2022.04.001 – volume: 249 start-page: 118 issue: 1 year: 2009 ident: 5203_CR27 publication-title: Ann Surg doi: 10.1097/SLA.0b013e3181904988 – volume: 380 start-page: 1450 issue: 15 year: 2019 ident: 5203_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMra1713263 – volume: 9 start-page: 60 issue: 1 year: 2023 ident: 5203_CR4 publication-title: Cell Discov doi: 10.1038/s41421-023-00563-x – volume: 13 start-page: 152 issue: 1 year: 2021 ident: 5203_CR9 publication-title: Genome Med doi: 10.1186/s13073-021-00968-x – volume: 2 start-page: 197 issue: 3 year: 2018 ident: 5203_CR28 publication-title: Ann Gastroenterol Surg doi: 10.1002/ags3.12057 – volume: 42 start-page: 535 issue: 4 year: 2005 ident: 5203_CR29 publication-title: J Hepatol doi: 10.1016/j.jhep.2004.11.042 – volume: 9 start-page: 17259 issue: 1 year: 2019 ident: 5203_CR2 publication-title: Sci Rep doi: 10.1038/s41598-019-53863-2 – volume: 7 start-page: 12870 issue: 1 year: 2017 ident: 5203_CR7 publication-title: Sci Rep doi: 10.1038/s41598-017-12834-1 – volume: 12 start-page: 1420 issue: 6 year: 1990 ident: 5203_CR5 publication-title: Hepatology doi: 10.1002/hep.1840120625 – volume: 11 start-page: 5542 issue: 1 year: 2021 ident: 5203_CR19 publication-title: Sci Rep doi: 10.1038/s41598-021-85223-4 – volume: 10 start-page: 5667 year: 2018 ident: 5203_CR30 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S177430 – volume: 8 start-page: 537 year: 2006 ident: 5203_CR11 publication-title: Annu Rev Biomed Eng doi: 10.1146/annurev.bioeng.8.061505.095802 – volume: 13 start-page: 3290 issue: 6 year: 2022 ident: 5203_CR14 publication-title: J Gastrointest Oncol doi: 10.21037/jgo-22-1238 – volume: 62 start-page: 793 issue: 5 year: 2023 ident: 5203_CR20 publication-title: Clin Chem Lab Med doi: 10.1515/cclm-2023-1037 – volume: 11 start-page: 2691 year: 2019 ident: 5203_CR26 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S191287 – volume: 10 start-page: 496 year: 2020 ident: 5203_CR6 publication-title: Front Oncol doi: 10.3389/fonc.2020.00496 – volume: 29 start-page: 1043 issue: 7 year: 2003 ident: 5203_CR22 publication-title: Intensive Care Med doi: 10.1007/s00134-003-1761-8 – volume: 7 start-page: e42895 year: 2023 ident: 5203_CR10 publication-title: JMIR Form Res doi: 10.2196/42895 – volume: 13 start-page: 15683 issue: 1 year: 2023 ident: 5203_CR17 publication-title: Sci Rep doi: 10.1038/s41598-023-42964-8 |
| SSID | ssj0024549 |
| Score | 2.4817784 |
| Snippet | Background
Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore,... Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore, survival time... Background Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis. Therefore,... Data on patients with AFP-positive HCC were extracted from the Surveillance, Epidemiology, and End Results database. Six ML algorithms (extreme gradient... Abstract Background Patients with alpha-fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) have aggressive biological behavior and poor prognosis.... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 455 |
| SubjectTerms | Algorithms alpha-Fetoproteins - metabolism Area Under Curve Biomedical and Life Sciences Biomedicine Calibration Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Computational Modelling and Epidemiology Epidemiology Female Glycoproteins Hepatocellular carcinoma Hepatoma Humans Liver Neoplasms - blood Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - pathology Machine Learning Male Medical research Medicine, Experimental Medicine/Public Health Predictive analytics Prognosis ROC Curve Survival XGBoost algorithm |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwEB5BQYgL-xIoyEhIHMBqHCd59rEgKg5QIZaqNyvx0j6JJtVL2op_z4yTPJqCKsE19kheZs2MvwF4SZkZjCsqHgiBMFep53XhFMerLiqdhTyP_zv2Pi52d9X-vv48Pgrrpmr3KSUZNXUUa1VudWiZUKjRpnCq3ZD87CpcQ3OnqGHDl697vxH2MOSZnsf8lW5mgiJS_5_6-JxBulgseSFjGg3Rzu3_28IduDU6nmx74JS7cMU39-DGpzG1fh9-nisfYm1gFTuKdZaejY0lDjhZPMdi7xzWt-x4RcQ9oxKvpu2WXSSjt7s8-L6NCBDLhg9lYaeeHaLl61vKFFDpK7PUxahpj6oH8H3n_bd3H_jYl4HbQqU9rx31rbJ5VqlKO51LVVHgYRfeh8ymITjpanQ0nXWoEqpahFwHdAPqUtTau1I-hI2mbfxjYEJZtKHSBilDXqP2SB26JIUsdJ1ZsbAJiOmqjB1By6l3xg8TgxdVmuFMDZ6piWdqzhJ4vaY5HiA7Lp39ljhgPZPgtuOHdnVgRuk1Ms1wXULpNGBEpRz96C5tXVapVzZoncAr4h9DSgGXZ6vxbQNukuC1zDahEAohhUxgczYThdnOhl9MHGhoiCrgGt-edLgEjC2lRo2ZwKOBI9drlgr9QnSsE1AzXp1taj7SLA8jljgBzma4pwTeTCxrRi3WXXJqT_5t-lO4mQ1cz4XchI1-deKfwXV72i-71fMovr8AgJZCeA priority: 102 providerName: Springer Nature |
| Title | Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma |
| URI | https://link.springer.com/article/10.1186/s12967-024-05203-w https://www.ncbi.nlm.nih.gov/pubmed/38741163 https://www.proquest.com/docview/3054839319 https://pubmed.ncbi.nlm.nih.gov/PMC11092049 https://doaj.org/article/302d821890f0498d9ff76cb6a0e8cf99 |
| Volume | 22 |
| WOSCitedRecordID | wos001221748900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RSV dateStart: 20030601 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9UwFA86RfYifts5LxEEHzSsbXrb5HGTDQV3uUwd16eQ5sNdcO247Tb87z0nbS-3E-aLL4U0CSQ5XznJye8Q8hZvZsCv0MwjAmEmYsfKqRUMSD3VMvVZFs47Tr8Us5lYLOR8I9UXxoR18MDdwu3xOLUC7JCMPWxmhcUzxtyUuY6dMF6Gp3txIQdnakDZA7dneCIj8r0GrBooBPjPMO6Ds-uRGQpo_X_r5A2jdDNg8sataTBGR4_Iw34XSfe70T8md1z1hDw47u_Jn5LfG7FAtPZU0_MQNOlonyXiJ0PzZWlIhEPbml6ssHNLMV6rqptlE7rhQ1zmXVsHOIdlxboYrytHz8CMtTUe-2McKzWYkqiqz_Uz8v3o8NvHT6xPssDMVMQtKy0moTJZqoWWVmZcaPQiTOGcT03sveW2hF2jNRbkW5eJz6QHm17mSSmdzflzslXVlXtJaCIMGERuPOc-K0EVxEA5xI-RZWqSwkQkGdZcmR6BHBNh_FLBExG56uikgE4q0EldR-T9us9Fh79xa-sDJOW6JWJnhx_AUarnKPUvjorIO2QEhRIOwzO6f6gAk0SsLLWPkIJJwhMekd1RS5BMM6p-M7CSwioMZ6tcfdnAEMBR5BLUX0RedKy1HjMXsMmDXXJExIjpRpMa11TLswAMjuixKcwpIh8G_lS9SmpuWbWd_7Fqr8h22skXS_gu2WpXl-41uW-u2mWzmpC7xaIIXzEh9w4OZ_OTSZBYKM0_H89_QOnk6-kf_CxDqA |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5BQcAL9xEoYCQkHqhFEmez9mNBVEVsVwhK1Tcr8dGuRJNqk7bi3zPjJEtTUCV4jT2Sjzkz428AXlNmBuOKgntCIMxk7Hg5sZLjVU8KlfosC_879mbT-Vzu76sv_aOwZqh2H1KSQVMHsZb5uwYtEwo12hROtRuCn12FaxlaLELM__pt7zfCHoY8w_OYv9KNTFBA6v9TH58zSBeLJS9kTIMh2rrzf1u4C7d7x5NtdpxyD6646j7c2OlT6w_g57nyIVZ7VrCjUGfpWN9Y4oCTxbMs9M5hbc2Ol0TcMirxqupm0QQyervLvWvrgACxqHhXFnbq2CFavramTAGVvjJDXYyq-qh4CN-3Pu5-2OZ9XwZuJjJueWmpb5XJ0kIWyqpMyIICDzN1zqcm9t4KW6KjaY1FlVCUic-URzegzJNSOZuLR7BW1ZV7AiyRBm2oMF4In5WoPWKLLslETFSZmmRqIkiGq9KmBy2n3hk_dAheZK67M9V4pjqcqT6L4O2K5riD7Lh09nvigNVMgtsOH-rlge6lV4s4xXUlUsUeIypp6Ud3bsq8iJ00XqkI3hD_aFIKuDxT9G8bcJMEr6U3CYUwSUQiIlgfzURhNqPhVwMHahqiCrjK1ScNLgFjS6FQY0bwuOPI1ZqFRL8QHesI5IhXR5saj1SLw4AlToCzKe4pgo2BZXWvxZpLTu3pv01_CTe3d3dmevZp_vkZ3Eo7CeCJWIe1dnninsN1c9oumuWLIMq_AJ-SRVw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ra9RAEB-0SvFLfdto1RUEP-jSJJvL7X6sj0OxHgW19NuS7KM9sMlxSVv8753Z5M5LlYL4NbsL-5hnZuY3AC8pMoN-RcE9IRBmMna8HFnJ8alHhUp9loX_HYf74-lUHh2pg7Uq_pDtvgxJdjUNhNJUtbtz6zsWl_lug1oKGRz1C6c8DsEvrsONjBLpyV__evgbbQ_dn2WpzF_XDdRRQO3_UzavKafLiZOXoqdBKU1u__9x7sBWb5CyvY6C7sI1V92DzS99yP0-_FxLK2K1ZwU7DfmXjvUNJ445aULLQk8d1tZsvqDFLaPUr6puZk1YRjW93Lu2DsgQs4p36WLnjp2gRmxriiBQSiwz1N2oqk-LB_B98uHbu4-879fAzUjGLS8t9bMyWVrIQlmVCVmQQ2LGzvnUxN5bYUs0QK2xKCqKMvGZ8mgelHlSKmdz8RA2qrpy28ASaVC3CuOF8FmJUiW2aKqMxEiVqUnGJoJk-Wza9GDm1FPjhw5Ojcx1d6ca71SHO9UXEbxerZl3UB5Xzn5L1LCaSTDc4UO9ONY9V2sRp7ivRKrYo6clLf0Az02ZF7GTxisVwSuiJU3CArdnir7mAQ9JsFt6j9AJk0QkIoKdwUxkcjMYfrGkRk1DlBlXufqswS2gzykUStIIHnXUudqzkGgvosEdgRzQ7eBQw5FqdhIwxgmINsUzRfBmSb66l27NFbf2-N-mP4fNg_cTvf9p-vkJ3Eo7BuCJ2IGNdnHmnsJNc97OmsWzwNW_ABiFTkA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+machine+learning-based+model+to+predict+prognosis+of+alpha-fetoprotein-positive+hepatocellular+carcinoma&rft.jtitle=Journal+of+translational+medicine&rft.au=Bingtian+Dong&rft.au=Hua+Zhang&rft.au=Yayang+Duan&rft.au=Senbang+Yao&rft.date=2024-05-13&rft.pub=BMC&rft.eissn=1479-5876&rft.volume=22&rft.issue=1&rft.spage=1&rft.epage=10&rft_id=info:doi/10.1186%2Fs12967-024-05203-w&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_302d821890f0498d9ff76cb6a0e8cf99 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |